Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;96(51):e9322.
doi: 10.1097/MD.0000000000009322.

Arterial stiffness assessment in patients with phenylketonuria

Affiliations

Arterial stiffness assessment in patients with phenylketonuria

Alvaro Hermida-Ameijeiras et al. Medicine (Baltimore). 2017 Dec.

Abstract

In patients with phenylketonuria (PKU) compliant to diet greater tendency to overweight and higher inflammatory biomarkers levels than controls were reported. Although this could lead to atherogenesis, the elastic properties of large arteries in PKU patients have never been assessed. The aim of this study was to assess arterial stiffness measured by applanation tonometry in PKU patients compared to healthy controls.We carried out a cross-sectional study in 41 PKU patients (range age: 6-50 years old) and 41 age- and gender-matched healthy controls. Evaluated data included pharmacological treatment with sapropterin, clinical, and biochemical parameters. Aortic stiffness was assessed noninvasively by applanation tonometry measuring central blood pressure, aortic augmentation index (Aix@HR75), augmentation pressure (AP), and pulse wave velocity (PWV).We found higher PWV in classic PKU patients (6.60 m/second vs 5.26 m/second; P: .044). Percentage of PKU patients with PWV above 90 percentile was higher than controls (14.63% vs 2.32%; P: .048). A positive relationship was observed between the annual Phe median and PWV (r: 0.496; P: .012). PKU subjects with lower Phe tolerance showed more body weight (67.6 kg vs 56.8 kg; P: .012) and more PWV than those with higher Phe tolerance (6.55 m/second vs 5.42 m/second; P: .044).Our data show increased aortic stiffness in PKU patients, measured by applanation tonometry, when compared to healthy controls. Higher Phe levels are associated with a bigger PWV increase, which is not present in those subjects compliant to diet or under sapropterin treatment. These results could have marked effects in both research and clinical daily practice for a proper evaluation of cardiovascular risk in PKU subjects.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Box plot of pulse wave velocity according to phenylketonuria phenotype. The X-axis indicates the controls, mild–moderate PKU, and classic PKU groups. Box plots show mean values (solid horizontal line); 25th and 75th percentiles (box); minimum and maximum values (bars); outliers (open circles). The indicates the statistical significant differences: P < .05, using the statistical tests described in the Subjects and Methods Section.
Figure 2
Figure 2
Linear correlation between annual median Phe levels and carotid-femoral PWVin patients with mild–moderate and classic phenylketonuria (PWV = 4.34 + 0.2 × annual Phe median).
Figure 3
Figure 3
Correlations between anthropometric measurements and pulse wave velocity in patients with mild–moderate and classic phenylketonuria. Linear correlation between PWV and (A) weight (PWV = 1.62 + 0.07 × weight), (B) waist perimeter (PWV = 0.74 + 0.08 × waist perimeter), and (C) body mass index (PWV = 0.68 + 0.22 × body mass index).

References

    1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417–27. - PubMed
    1. Martínez-Pardo M, Marchante C, Dalmau J, et al. Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. An Esp Pediatr 1998;114:3–8.
    1. Okano Y, Nagasaka H. Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab 2013;110:424–30. - PubMed
    1. Mirás A, Bóveda MD, Leis MR, et al. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab 2013;108:149–54. - PubMed
    1. Giovannini M, Verduci E, Salvatici E, et al. Phenylketonuria: nutritional advances and challenges. Nutr Metab 2012;9:1–7. - PMC - PubMed